A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and cervical malignancies who are undergoing LN mapping.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Feasibility Study of the "Easy Light" Fluorecence Imaging System

NCT05004623

Uterine Cervical Neoplasms Uterine Neoplasms

COMPLETED NA

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer

NCT05704283

Breast Carcinoma

RECRUITING EARLY_PHASE1

Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies

NCT01384357

Lymphadenopathy Malignancy

COMPLETED

A Real-time and Computerized Sonographic Reporting System in Predicting Malignant Cervical Lymphadenopathy

NCT01130402

Lymphadenopathy

COMPLETED

Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer

NCT02019303

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Cancer Uterine Cancer Cervical Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blue - PINPOINT

The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.

Group Type ACTIVE_COMPARATOR

PINPOINT

Intervention Type DEVICE

PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes

PINPOINT - Blue

The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.

Group Type ACTIVE_COMPARATOR

PINPOINT

Intervention Type DEVICE

PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PINPOINT

PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Subjects with FIGO Clinical Stage I endometrial cancer undergoing minimally invasive hysterectomy with lymph node mapping.
* Subjects with FIGO Clinical Stage IA cervical cancer ≤ 2 cm in size undergoing minimally invasive hysterectomy, trachelectomy, or conization with lymph node mapping. Subjects with clinical Stage IA1 cervical cancer without lympho vascular space involvement (LVSI) and negative margins on cone biopsy are not to be included.
* Subjects with negative nodal status (N0)
* Subjects with negative metastatic involvement (M0).

Exclusion Criteria

* Have had prior dissection and/or radiation in pelvis.
* Advanced cervical or endometrial cancer, T3/T4 lesions
* Diagnosis of cervical cancer with a tumor size greater than 2 cm.
* Locally advanced or inflammatory cervical or uterine cancer
* Metastatic cervical or uterine cancer.
* Known allergy or history of adverse reaction to ICG, iodine or iodine dyes.
* Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.
* Hepatic dysfunction defined as MELD Score \> 12.
* Renal dysfunction defined as serum creatinine ≥ 2.0 mg/dl.
* Subjects who have participated in another investigational study within 30 days prior to surgery.
* Pregnant or lactating subjects.
* Subjects who, in the Investigator's opinion, have any medical condition that makes the subject a poor candidate for the investigational procedure, or interferes with the interpretation of study results.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No